CoNCERT: Corporate Presentation (Concert Pharma) - Apr 17, 2015 - "CTP-499 Benefit Greater in Patients with Higher Baseline UACR"; "48 Week Serum Creatinine Levels Rise More in Patients with Higher Baseline UACR"; "Higher UACR is known to correlate with more rapid disease progression"; "FDA supportive of enriched population in Phase 3 development"; "CTP-499: Statistically Significant Changes Observed in Biomarkers"; "CTP-499 benefit most evident in patients with actively progressing disease"
P2 data • Renal Disease
|